Glycemic control, blood pressure control, and single-agent renin-angiotensin-aldosterone system (RAAS) blockade were, until recently, the pillars of managing diabetic kidney disease (DKD). Although the introduction of sodium/glucose cotransporter 2 (SGLT2) inhibitors has further reduced DKD progression, patients continue to have significant residual risk, underlying the importance of identifying new therapies. In FIDELIO-DKD, Bakris et al1 demonstrate that the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (once daily 10-20 mg), on top of standard of care, is beneficial in DKD management.